US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Shows

Although glucagon-like peptide-1 (GLP-1) agonists have shown promising results in reducing weight and cardiovascular risks, new data reveals that many U.S. adults struggle to stay on long-term treatment.

While newer obesity-indicated GLP-1 therapies, such as semaglutide and tirzepatide, are increasingly used, poor persistence rates threaten the clinical and economic benefits of these medications.

Novo Nordisk A/S' (NYSE:NVO) semaglutide is the main input in Ozempic and Wegovy, and tirzepatide is a key ingredient in Eli Lilly & Co's (NYSE:LLY) Mounjaro and Zepbound.

Also Read: Novo's India Move Could Reshape The Weight-Loss Drug War With Eli Lilly

GLP-1 agonists have been linked to 10% to 20% weight loss in clinical trials, with some studies also showing reduced cardiovascular events in individuals without diabetes.

Yet, ...